News &amp; Updates

Treatment with ambroxol in patients with Parkinson’s disease dementia (PDD) is safe and well tolerated but falls short of improving cognition, according to a single-centre phase II study.

Ambroxol safe but fails to improve cognition in Parkinson’s disease dementia

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

11 Jul 2025 by

First-line nurulimab and prolgolimab combination therapy demonstrated superior efficacy compared with prolgolimab monotherapy in patients with unresectable or metastatic melanoma, according to the OCTAVA trial presented at AACR 2025.

Nurulimab-prolgolimab superior to prolgolimab alone in metastatic melanoma

Semaglutide significantly reduced the risk of MACE by 20% in individuals with CVD + obesity

In the large multicentre, double-blind, placebo-controlled SELECT trial, semaglutide 2.4 mg significantly reduced the risk of major adverse cardiovascular events (MACE) by 20 percent in individuals with cardiovascular disease (CVD) and obesity. The MACE curves separated early before maximal weight loss, suggesting CV benefits beyond weight reduction.

Semaglutide significantly reduced the risk of MACE by 20% in individuals with CVD + obesity

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial

Twelve weeks of treatment with the aldosterone synthase inhibitor lorundrostat proved efficacious and safe for lowering blood pressure (BP) in adults with uncontrolled hypertension, including those who were resistant to treatment, according to the phase III Launch-HTN trial.

Lorundrostat for uncontrolled hypertension hits efficacy, safety targets in phase III trial

10 Jul 2025

Children with UI, psychiatric disorder perform poorly in school

Urinary incontinence (UI) does not appear to affect the performance of children in school, reports a recent study.

Children with UI, psychiatric disorder perform poorly in school

Deucravacitinib delivers superior efficacy, safety in active PsA

Deucravacitinib exhibits superiority over placebo in terms of overall disease activity measures, musculoskeletal and dermatologic manifestations, and quality of life in adults with active psoriatic arthritis (PsA) who are naïve to biologic disease-modifying antirheumatic drugs (DMARDs), according to the results of the POETYK PsA-1 study.

Deucravacitinib delivers superior efficacy, safety in active PsA

10 Jul 2025

Larger prostate glands improve faster after thermal therapy

Patients with benign prostatic hyperplasia undergoing convective water vapor thermal therapy (CWVTT) enjoy significant improvements in lower urinary tract symptoms (LUTS) across the prostate volume (PV) spectrum. Notably, medium and large glands appear to show faster improvement than small ones.

Larger prostate glands improve faster after thermal therapy

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

Treatment with retatrutide—an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors—appears to result in greater total body fat mass reduction in individuals with type 2 diabetes (T2D) and high BMI when compared with placebo and dulaglutide, according to a substudy of a phase II trial.

Investigational triple–hormone-receptor agonist reduces fat mass in people with T2D

ADHD medications’ real-world benefits diminish as prescription rate rises

Attention-deficit/hyperactivity disorder (ADHD) medications are associated with reduced risks of several serious real-world outcomes, but the magnitude of these associations has decreased alongside rising prescription rates, a nationwide study has shown.

ADHD medications’ real-world benefits diminish as prescription rate rises

10 Jul 2025

Pembrolizumab + CCRT ups survival in high-risk LACC

Treatment with the combination of pembrolizumab and concurrent chemoradiotherapy (CCRT), followed by pembrolizumab maintenance, led to a sustained, long-term survival benefit in patients with high-risk, locally advanced cervical cancer (LACC) compared with CCRT alone, according to the final analysis of the phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 trial presented at ASCO 2025.

Pembrolizumab + CCRT ups survival in high-risk LACC